Alinari et al. described how the synthetic sphingosine analogue, FTY720, potentiated the Milatuzumab onco-immunosuppressive effects in MCL by blocking the autophagy-lysosome dependent degradation of CD74 [190]. This evidence concerns the gene CD74 and mantle cell lymphoma.